GLAUKOS Corp

GKOS 10-K · FY 2025
API behind this page

GKOS FY 2025 request

Playground key active
Request URL /api/financials?ticker=GKOS&year=2025&quarter=4&full_year_mode=true
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric FY 2025 FY 2024 YoY
Revenue 507,442 383,481 +32.3%
Show Product Lines breakouts
Corneal Health 86,372 80,205 +7.7%
Corneal Health · Non Us 9,918 9,682 +2.4%
Corneal Health · US 76,454 70,523 +8.4%
Glaucoma 421,070 303,276 +38.8%
Glaucoma · Non Us 122,482 103,705 +18.1%
Glaucoma · US 298,588 199,571 +49.6%
Show Business Segments breakouts
Development and Commercialization of Ophthalmic Therapies 507,442 383,481 +32.3%
Show Geography breakouts
Non Us 132,400 113,387 +16.8%
US 375,042 270,094 +38.9%
Cost of Revenue 111,814 94,027 +18.9%
Show Business Segments breakouts
Development and Commercialization of Ophthalmic Therapies 111,814 94,027 +18.9%
Cost Of Impairment Of Intangible Assets 112,867 — —
Show Business Segments breakouts
Development and Commercialization of Ophthalmic Therapies 112,867 — —
Gross Profit 282,761 289,454 -2.3%
Selling, General & Administrative 331,747 261,166 +27.0%
Research And Development Expense Excluding Acquired In Process Cost 150,614 136,425 +10.4%
Operating Expenses 482,361 411,820 +17.1%
Operating Income -199,600 -122,366 -63.1%
Interest And Other Income 10,714 11,105 -3.5%
Show Business Segments breakouts
Development and Commercialization of Ophthalmic Therapies -10,714 -11,105 +3.5%
Interest Expense -4,635 -10,040 +53.8%
Show Business Segments breakouts
Development and Commercialization of Ophthalmic Therapies 4,635 10,040 -53.8%
Other Non-Operating Income (Expense) 479 -6,288 +107.6%
Non-Operating Income (Expense) 6,558 -23,235 +128.2%
Income Before Taxes -193,042 -145,601 -32.6%
Income Tax Expense (Benefit) -5,351 771 -794.0%
Show Business Segments breakouts
Development and Commercialization of Ophthalmic Therapies -5,351 771 -794.0%
Net Income -187,691 -146,372 -28.2%
Show Business Segments breakouts
Development and Commercialization of Ophthalmic Therapies -187,691 -146,372 -28.2%
EPS (Basic) -3.28 -2.77 -18.4%
EPS (Diluted) -3.28 -2.77 -18.4%
Wtd Avg Shares (Basic) 57,190 52,755 +8.4%
Wtd Avg Shares (Diluted) 57,190 52,755 +8.4%
Research & Development (FY) — — —
Show Business Segments breakouts
Development and Commercialization of Ophthalmic Therapies 107,131 84,609 +26.6%
Sales & Marketing (FY) — — —
Show Business Segments breakouts
Development and Commercialization of Ophthalmic Therapies 161,837 140,094 +15.5%
General & Administrative (FY) — — —
Show Business Segments breakouts
Development and Commercialization of Ophthalmic Therapies 169,910 121,072 +40.3%
Comprehensive Income -187,003 -144,922 -29.0%

Balance Sheet

Balance Sheet
Metric FY 2025 FY 2024 YoY
Current Assets
Cash & Cash Equivalents 90,813 169,626 -46.5%
Available For Sale Securities Debt Securities 187,947 149,289 +25.9%
Show Financial Instrument breakouts
Asset Backed Securities 10,623 7,819 +35.9%
Bank Time Deposits 61,006 5,623 +984.9%
Commercial Paper Not Included With Cash And Cash Equivalents 10,813 — —
Corporate Debt Securities 36,110 16,938 +113.2%
Municipal bonds 2,225 3,018 -26.3%
US Treasury Securities 67,170 115,891 -42.0%
Accounts Receivable 108,608 60,744 +78.8%
Inventory 63,564 57,678 +10.2%
Prepaid Expenses & Other Current Assets 24,052 12,455 +93.1%
Total Current Assets 474,984 449,792 +5.6%
Non-Current Assets
Restricted Cash And Cash Equivalents Noncurrent 3,834 4,733 -19.0%
Property, Plant & Equipment 113,253 97,867 +15.7%
Show Geography breakouts
Non Us 199 141 +41.1%
US 113,054 97,726 +15.7%
Operating Lease Right-of-Use Assets 31,527 30,254 +4.2%
Goodwill 66,710 66,134 +0.9%
Deposit Assets And Other Assets Noncurrent 21,859 20,715 +5.5%
Total Assets 893,487 974,756 -8.3%
Intangible Assets 134,716 144,545 -6.8%
Show Finite Lived Intangible Assets By Major Class breakouts
Epioxa Developed Technology 108,597 — —
Leases Acquired In Place 321 — —
Licensing Agreements 4,755 5,107 -6.9%
Mobius Developed Technology and Customer Relationships 16,564 — —
Photrexa Developed Technology 4,479 139,438 -96.8%
Show Type Of Arrangement breakouts
License Agreement with Celanese 4.8 — —
Other Assets
Finance Lease Right Of Use Asset 39,404 41,816 -5.8%
Intangible Assets Net Excluding Goodwill 141,916 263,445 -46.1%
Current Liabilities
Accounts Payable 24,624 13,026 +89.0%
Accrued Liabilities 76,651 62,099 +23.4%
Total Current Liabilities 101,275 75,125 +34.8%
Non-Current Liabilities
Operating Lease Liabilities 35,767 33,936 +5.4%
Finance Lease Liability Noncurrent 68,109 69,463 -1.9%
Deferred Tax Liabilities 441 6,928 -93.6%
Other Non-Current Liabilities 31,740 22,373 +41.9%
Total Liabilities 237,332 207,825 +14.2%
Stockholders' Equity
Common Stock 58 56 +3.6%
Additional Paid In Capital Common Stock 1,586,056 1,509,831 +5.0%
Accumulated Other Comprehensive Income 3,303 2,615 +26.3%
Retained Earnings -933,130 -745,439 -25.2%
Treasury Stock Common Value -132 -132 0.0%
Total Stockholders' Equity 656,155 766,931 -14.4%
Total Liabilities & Equity 893,487 974,756 -8.3%

Cash Flow Statement

Cash Flow Statement
Metric FY 2025 FY 2024 YoY
Operating Activities
Net Income -187,691 -146,372 -28.2%
Show Equity Components breakouts
Retained Earnings -187,691 -146,372 -28.2%
Depreciation 10,965 10,949 +0.1%
Amortization Of Intangible Assets 27,128 24,701 +9.8%
Show Income Statement Location breakouts
Cost Of Sales 26.8 22.2 +20.7%
Selling General And Administrative Expenses 0.4 2.5 -84.0%
Impairment Of Intangible Assets Excluding Goodwill 112,867 — —
Operating Lease Right Of Use Asset Amortization Expense 4,252 4,272 -0.5%
Change In Deferred Income Tax Expense Benefit -6,487 -216 -2903.2%
Gain Loss On Sale Of Property Plant Equipment 32 598 -94.6%
Stock-Based Compensation 63,218 50,207 +25.9%
Foreign Currency Transaction Gain Loss Unrealized -1,216 4,620 -126.3%
Amortization Of Discount On Short Term Investments -2,981 -4,045 +26.3%
Increase Decrease In Others Accrued Liabilities 1,782 5,206 -65.8%
Provision For Doubtful Accounts 7,379 -91 +8208.8%
Inventory Write Down 2,645 4,449 -40.5%
Show Finite Lived Intangible Assets By Major Class breakouts
In Process Research And Development 2.6 — —
Provision For Excess And Obsolete Inventory 1,339 662 +102.3%
Change in Accounts Receivable -53,020 -21,875 -142.4%
Change in Inventory -7,702 -19,450 +60.4%
Increase Decrease In Prepaid Expense And Other Current Assets -11,296 3,334 -438.8%
Increase Decrease In Accounts Payable And Accrued Liabilities 18,824 21 +89538.1%
Increase Decrease In Other Noncurrent Assets 5,173 -2,075 +349.3%
Net Cash from Operations -14,789 -61,318 +75.9%
Depreciation & Amortization 38,093 35,650 +6.9%
Show Geography breakouts
Non Us 50 35 +42.9%
US 38,043 35,615 +6.8%
Show Fair Value By Asset Class breakouts
Property Plant And Equipment 11 10.1 +8.9%
Deferred Income Taxes -6,487 -216 -2903.2%
Investing Activities
Payments To Acquire Businesses Net Of Cash Acquired -12,437 — —
Payments To Acquire Other Productive Assets -16,607 — —
Capital Expenditures -7,666 -6,300 -21.7%
Payments To Acquire Marketable Securities -232,291 -189,955 -22.3%
Proceeds From Sale And Maturity Of Marketable Securities 196,938 247,199 -20.3%
Payments For Investment In Company Owned Life Insurance Policy -4,800 -3,151 -52.3%
Other Investing Activities Cash Flow Statement -750 — —
Net Cash from Investing -77,613 47,831 -262.3%
Noncash Or Part Noncash Acquisition Contingent Consideration 7,700 — —
Financing Activities
Proceeds From Stock Options Exercised 13,453 39,347 -65.8%
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans 7,686 7,416 +3.6%
Tax Withholding for Share Compensation -8,132 -6,563 -23.9%
Finance Lease Principal Payments -1,121 -877 -27.8%
Net Cash from Financing 11,886 91,540 -87.0%
Supplemental
Unpaid Capital Expenditures 2,920 909 +221.2%
Income Taxes Paid 949 1,360 -30.2%
Interest Paid 4,212 4,466 -5.7%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 804 -3,017 +126.6%
Net Change in Cash -79,712 75,036 -206.2%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 94,647 174,359 -45.7%

Values in thousands USD. Source: SEC EDGAR 10-K filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key